Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, that's me :)
Catfish I think we have much different situations. I think you've previously said you're near retirement age. Me, I'm thirty with a car payment and a mortgage on a "fixer-upper"....and with hopes of raising a family eventually.
I started this year with a measly $6,000 in my brokerage account....and $5,000 of it is borrowed from a credit card. I set some outlandish goals for quarterly profit targets just to keep enough income to keep up with the bills. I surprised myself when I actually met the first goal to earn 300% in 3 months, thanks mainly to your timely advice on SSPI and BOCX.
But I couldn't continue to meet those goals....and a good job came up.....so I'm working this contract job for as long as they'll let me.....and trying to manage the portfolio to have a little larger seed bank when I return to this in the spring.
Thanks to you, GPG, and the others that share your expertise to make these kinds of returns possible for the average guy like me.
I play catch up every night now....and sometimes check quotes byphone during the day.....but the regular paycheck is nice for now.
The only trades I've made recently is selling IIIN to buy SWTX, otherwise I'm just holding long-term positions in BIPH, EZEN, DFNS, PHPG, PSOL, ANII, ADGO, MDPA...and it's working out okay....for now.
The Baghdad Airport reopened today. I hate to say it, so I won't, but we know why it was closed....and what it has to do with PHPG.
I'm also one of the TWA flight 800 conspiracy theorists. The History channel had a compelling documentry on TWA flight 800 and the conspiracy theories.
I hope it never happens, but PHPG could do well just on their military business. It was nice to see a profit this quarter :)
I haven't checked his tour dates lately, thanks for the reminder. This is the kewlest stock message board out there :)
My first "show" was Phish the summer of '92 in the 'burgh (Pittsburgh). The Dead was to slow for me back then in my rambunctious youth, I finally caught a Dead show in the summer of '95, one of their last shows.
babycakes what happened to the cute picture of your cats?
Now you have a Keller Williams quote?
Personally, I'm saving for my "double decker double wide". :)
Golf thanks for the info., I find the IONN situation compelling, but might an "after the news" buyer there. Yes those that buy before the news might make some more, but it takes all kinds to make a market.
Golf how sure are you of those DOD sales? Is it only based on the 8/16/2004 PR?
Is IONN already on the GSA schedule...or do they already have a contract or delivery order? That PR only announced products had been added to the approved products list, which doesn't neccessarily translate to immediate sales.
Pardon my ignorance, I haven't done much DD, but have been watching.
I take it you didn't participate in the private placement?
Catfish,
No worries about work. I actually like the job I took now. Thanks to The Microcap Kitchen and the money I've made here, I've been able to be selective and avoid going back to hazardous waste consulting.
I'm actually pretty excited about this job. It's the kind of opportunity I've been holding out for. I'm working for a pharmaceutical company helping them prepare a research site for ISO 14001 certification in Environmental Management Systems. For now it's only a six month contract position, but it could turn into a permanent position if a few things fall into place properly. Otherwise I'll be back full-time in February?
I still have money in the market, but don't have an internet connection at work, so I have it in what I feel are somewhat safer stocks......yes I still have a considerable sum in BIPH.
I changed my screen name to get back on SI. I'm not sure what the problem was, I hope I didn't offend anyone.
Thanks....I'll still be around.
Am I the only one having problems with The SI site? I can't log on, or view The Micrcap Kitchen.
If I am the only one having problems, would someone mind asking Coz why? Did I do something wrong?
P.S.: I have a full-time job now again, just started last Thursday, so I will only be checking in here in the evenings and on the weekends. I'm a little bummed I'm not able to check-in tonight to see what happened today.
TIA for any help.
Stuki, I'm relieved to see that's all it is. From the limited information of your initial post, I was worried it could have been something much worse, dealing with how BSX invests in its smaller companies.
Yes it's a little problem for BSX, but nothing more than a little bump in the road. It dsoes go to show you need to watch your cards when dealing with the big players, but BIPH seams to be on top of that game with all their recent patent applications pertaining to stent designs.
No...I chased it...but with the value prospect I feel somewhat safe.
What do you guys tink of IIIN going to the NASDAQ tommorrow?
I've seen some good value stocks flop once they get listed (GEXA)....and I've seen some fly.
What's the experts read on the technicals?
King that URL didn't work. I would like to read that story. BSX is pretty well known for investing in their partners, knowing full well what the agreement with BSX will do for the market value of their smaller partners.
Catfish, thanks for the heads-up about SI. It's nice to be able to post on SI! So many times I have had something I would like to contribute...or something I would like to ask....but couldn't do a thing.
With only 3 posts/day, I'll probably continue to post here to....and yes...it's good to have a back up to.
Both I-hub and SI are nice SPAM free forums!
BIPH fans, we got news again!
Is it just me, or is their "non-disclosure" work with Boston Scientific becoming painfully obvious?
Two New Issued Patents and 12 New Patent Applications Cement Biophan Technologies' Leading-Edge Role in Biomedical Technology
Friday September 24, 4:01 pm ET
New Patents Outline Significant Advances in Broad Range of Medical Applications
ROCHESTER, N.Y.--(BUSINESS WIRE)--Sept. 24, 2004-- Biophan Technologies, Inc. (OTC BB: BIPH - News), a developer of next-generation biomedical technology, today announced the filing of 12 new patents in a range of medical applications that further establish the Company's cutting-edge role in several critical areas of medical science and health care.
The patents, filed by Biophan and its associated companies, Nanoset LLC and Biomed Solutions LLC, outline new advances in the use of Magnetic Resonance Imaging (MRI), as well as nanotechnology coatings, biothermal batteries and opto-electric controls for implanted medical devices.
The two newly issued patents and 12 filed applications expand Biophan's extensive intellectual property portfolio from 80 to a total of 92 issued, pending, owned or licensed patents. The new total includes 21 issued patents and 71 pending, representing a significant strengthening of the Company's prominent leadership position in advanced aspects of biomedical technology.
The new patents and applications involve the following areas:
Nine of the newly filed patents are related to the Company's 'anti-antenna' geometries for stent designs, enabling the manufacture of stents that do not interfere with MRI imaging of the stent interior - a process critical to diagnosing the healing process and detecting new blockage due to plaque or tissue accumulation. This anti-antenna technology effectively "de-tunes" the stents so they don't interfere with the radio frequencies used in MRI. The new stent designs can be used independently or in concert with Biophan's previously announced nanomagnetic coatings that improve MRI imaging. The coatings provide an additional method of MRI image compatibility for stents.
One additional patent applies similar anti-antenna design techniques to medical device leads, catheters and guidewires used in MRI-guided surgery. The new design prevents adverse heating to those devices caused by the MRI radio-frequency fields, and with the previous technologies solves the problems of safety and image compatibility that have impeded the development of MRI interventional medicine.
Another application extends the firm's technology in nanomagnetic coatings, as well as manufacturing processes used to create and apply them.
An additional application relates to biothermal power sources used for pacemakers and other implanted devices, expanding Biophan's coverage to three patents in this area.
In addition, the US Patent office on Sept. 21 issued two previously filed Biophan applications for designs enabling MRI-compatible uses of opto-electronics in pacemakers and other implanted devices.
"These new patents demonstrate both the depth as well as the rapid rate of Biophan's innovation in a range of areas of biomedical science and health care," said Mr. Weiner. "We are excited about these new milestones in the broadening of our intellectual property portfolio, and about the new opportunities they provide for development and growth of new sources of revenue, and value for our shareholders."
Biophan continues to file patent applications on multiple technologies being developed to solve the complex problems associated with MRI imaging in the presence of implanted devices or surgical tools. The technologies include a range of systems and techniques, including opto-electronics, nanomagnetic coatings, carbon composite coatings, software techniques and specialized device geometries. These can be used individually or in combination.
Other devices benefiting from these techniques include pacemakers, implanted cardioverter defibrillators, drug pumps, neurostimulators and surgical tools.
The performance improvements these technologies provide include reduction or elimination of unwanted tissue and device heating, elimination of unwanted electrical stimulation of nerve tissue, improved MRI imaging of otherwise invisible implants or surgical tools and clear imaging of tissues near or inside these implanted devices.
By eliminating the difficulties and dangers associated with MRI imaging of these devices, Biophan is expanding the uses of MRI as well as bringing its benefits to patients who are currently denied the valuable technology due to safety issues or unusable images.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 21 issued U.S. patents and 71 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
BIPH might be doing a little booshing Monday, but the biggest boosh is yet to come IMHO:
Is it just me, or is their "non-disclosure" work with Boston Scientific becoming painfully obvious?
Two New Issued Patents and 12 New Patent Applications Cement Biophan Technologies' Leading-Edge Role in Biomedical Technology
Friday September 24, 4:01 pm ET
New Patents Outline Significant Advances in Broad Range of Medical Applications
ROCHESTER, N.Y.--(BUSINESS WIRE)--Sept. 24, 2004-- Biophan Technologies, Inc. (OTC BB: BIPH - News), a developer of next-generation biomedical technology, today announced the filing of 12 new patents in a range of medical applications that further establish the Company's cutting-edge role in several critical areas of medical science and health care.
The patents, filed by Biophan and its associated companies, Nanoset LLC and Biomed Solutions LLC, outline new advances in the use of Magnetic Resonance Imaging (MRI), as well as nanotechnology coatings, biothermal batteries and opto-electric controls for implanted medical devices.
The two newly issued patents and 12 filed applications expand Biophan's extensive intellectual property portfolio from 80 to a total of 92 issued, pending, owned or licensed patents. The new total includes 21 issued patents and 71 pending, representing a significant strengthening of the Company's prominent leadership position in advanced aspects of biomedical technology.
The new patents and applications involve the following areas:
Nine of the newly filed patents are related to the Company's 'anti-antenna' geometries for stent designs, enabling the manufacture of stents that do not interfere with MRI imaging of the stent interior - a process critical to diagnosing the healing process and detecting new blockage due to plaque or tissue accumulation. This anti-antenna technology effectively "de-tunes" the stents so they don't interfere with the radio frequencies used in MRI. The new stent designs can be used independently or in concert with Biophan's previously announced nanomagnetic coatings that improve MRI imaging. The coatings provide an additional method of MRI image compatibility for stents.
One additional patent applies similar anti-antenna design techniques to medical device leads, catheters and guidewires used in MRI-guided surgery. The new design prevents adverse heating to those devices caused by the MRI radio-frequency fields, and with the previous technologies solves the problems of safety and image compatibility that have impeded the development of MRI interventional medicine.
Another application extends the firm's technology in nanomagnetic coatings, as well as manufacturing processes used to create and apply them.
An additional application relates to biothermal power sources used for pacemakers and other implanted devices, expanding Biophan's coverage to three patents in this area.
In addition, the US Patent office on Sept. 21 issued two previously filed Biophan applications for designs enabling MRI-compatible uses of opto-electronics in pacemakers and other implanted devices.
"These new patents demonstrate both the depth as well as the rapid rate of Biophan's innovation in a range of areas of biomedical science and health care," said Mr. Weiner. "We are excited about these new milestones in the broadening of our intellectual property portfolio, and about the new opportunities they provide for development and growth of new sources of revenue, and value for our shareholders."
Biophan continues to file patent applications on multiple technologies being developed to solve the complex problems associated with MRI imaging in the presence of implanted devices or surgical tools. The technologies include a range of systems and techniques, including opto-electronics, nanomagnetic coatings, carbon composite coatings, software techniques and specialized device geometries. These can be used individually or in combination.
Other devices benefiting from these techniques include pacemakers, implanted cardioverter defibrillators, drug pumps, neurostimulators and surgical tools.
The performance improvements these technologies provide include reduction or elimination of unwanted tissue and device heating, elimination of unwanted electrical stimulation of nerve tissue, improved MRI imaging of otherwise invisible implants or surgical tools and clear imaging of tissues near or inside these implanted devices.
By eliminating the difficulties and dangers associated with MRI imaging of these devices, Biophan is expanding the uses of MRI as well as bringing its benefits to patients who are currently denied the valuable technology due to safety issues or unusable images.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 21 issued U.S. patents and 71 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Profit...the SI version is the one to watch....that's where Gary posts.
The Microcap Kitchen board is a little slow....and it is more about long term investing in emerging microcap stocks. Gary P Grobbel is the most notable poster there. He has a real good knack for finding good companies early. The minimum standards of the board assure that only relatively good quality companies are discussed there. For example he found TRLG this spring when it was trading around $1, BIPH last fall around $0.20, EZEN this spring around $0.30, and several other multi-baggers for patient investors.
Here's the board:
http://www.siliconinvestor.com/stocktalk/subject.gsp?subjectid=50570
There's a sister board here, for those of us to cheap to join SI:
http://www.siliconinvestor.com/stocktalk/subject.gsp?subjectid=50570
You might find some good picks there.
I've owned it from $0.50, before it was really clear that it could sustain profitability. Now it seams to be under accumulation, but I'm not much of a TA trader.
I just follow the picks from The Microcap Kitchen, are you guys familiar with that board? They find some good microcap stocks early.
I think my BIPH will Boosh again some day before the year is over, but that stock would probably bore the average trader. They have filed to change 15M shares to preffered shares for a strategic partner to make an equity investment. I think they might be developing into a simular business to ANPI, the company that licenses the coatings for Boston Scientific's stents. BIPH has been doing R&D with BSX for the past year.....no details are known yet...but I think it could be very good for BIPH....which is why it sustains a pretty high market cap for a company with 0 revenue.
Kewl....as far as stocks go....I think I'm a bit more of a long-term player than this board focuses on.
But my EZEN might be booshing today? Large float.....so it could break anyway quickly...but there's some value to support the price.
I just liked it because it was a zen stock, lol!
You guys know good music!
You gus like The Jazz Mandolin Project? How about Medesky Martin, & Wood?
PSOL getting hammered on the resignation of the CFO. Might be a good opportunity to do some bottom fishing?
Ask is now $0.14, they did a private placement at $0.23 earlier this year.
The company appears to be making progress at growing revenue...and this knee jerk reaction today may be overblown? Here's a summary of their current conditions:
Current Conditions
As discussed elsewhere in this Prospectus, we recently closed a Private Placement of our securities resulting in gross proceeds of approximately $3.3 million. We anticipate that the net proceeds from the Private Placement will be used to expand the sales and marketing efforts in the near term and for other general working capital purposes.
In 2004, we have begun to expand our sales and marketing capabilities to seek new sales opportunities for our products and services through our direct sales force and our relationships with communications infrastructure providers. The markets for these products have been and continue to be very competitive. Sales opportunities in the United States of America have continued to be limited due to the continued constrained economic conditions experienced by the communications industry, although we have begun to see improvements in the marketplace. While we believe there is a good opportunity to sell or license our solutions to Rural Broadband CSPs, the sales cycle in this market can be six months or longer because Rural Broadband CSPs are frequently publicly owned utilities and are subject to various regulatory requirements and agency oversight that can delay the timeline for a Rural Broadband CSP attempting to offer new services to its customers. While sales opportunities have been
19
--------------------------------------------------------------------------------
available in international markets, such as Asia-Pacific and Europe, currently we are not actively pursuing these geographic markets because of competition from larger competitors who have a local presence in these international markets, or locally based competitors in these international markets due to our current lack of a more fully-developed international sales and support capability.
During 2003, we successfully deployed our products and services into the "tier-one" Cable MSO and rural broadband markets, and have continued to focus on these domestic target markets. Additionally, we launched our application management and hosting services during 2003, and anticipate that these services will become an increasingly important element of our growth.
Our other notable activities and accomplishments during 2003 and the first six months of 2004 were as follows:
•
Increased our Connect IXC deployment support to a "tier-one" Cable MSO customer to assist this customer in rolling out its voice-over-IP networks ("VOIP") service to its cable markets during 2004.
•
Deployed Connect IXC for another "tier-one" Cable MSO for its rollout of VOIP services beginning later in 2004.
•
Deployed Connect CCB, an integrated customer care and billing solution, and Connect IXC at a municipal utility to support its rollout of VOIP, cable television services, and high-speed data services.
•
Entered into a multi-year agreement with a rural municipality to deploy its operation support systems on a "next generation" network to support voice, video and data services on the same network ("triple play").
•
Enhanced our products to provide additional value for the customers in our target markets.
•
Further established relationships with communication infrastructure providers who are active in the rural broadband market.
•
Increased our marketing activities to build market awareness of our solutions through increased participation in trade shows and other activities.
•
Continued assisting our largest customer in migrating from our legacy billing system to our new billing system.
•
Expanded our senior management team.
During 2003, we increased our cash balances by $66,000 to $1.25 million at December 31, 2003, and increased revenue by $389,000 to $6.5 million for the 12 months ended December 31, 2003. Despite our improvements, we do not expect to achieve profitability in the near future as we continue to invest in growing our business.
As discussed below, we recorded $534,000 of revenues from application management and hosting services during the first six months of 2004. We anticipate that these services will become an increasingly important element of our growth during the remainder of 2004.
We expect revenue to increase in the second half of 2004 and we expect services revenue to become a larger portion of total revenue as a result of the deployment of services to more customers. As we continue to build our services offering, we expect margins associated with services revenue to improve as certain fixed costs of services are leveraged to produce more services revenue. Working capital significantly improved in the second quarter of 2004 because of the closing of our $3.3 million Private Placement.
GregK there's a lot of BIPH fans. I assume you've seen the recent Pre14C filing requesting 15M shares be changed to preffered shares. The filing indicates the only difference will be liquidation rights, no special voting rights. It also indicates the investment can come in above the current market value. Special meeting is scheduled for early November.
Things look like they might be heating up there again before years end?
DFNS actually moving up a little here today. No momo, but it does have fundamentals:
Defense Industries International Reports Second Quarter 2004 Financial Results
Friday August 13, 3:19 am ET
ASHKELON, Israel--(BUSINESS WIRE)--Aug. 13, 2004--Defense Industries International, Inc. (OTCBB:DFNS - News), a leading manufacturer and global provider of personal military and civilian protective equipment and supplies, yesterday announced its financial results for the second quarter ended June 30, 2004.
ADVERTISEMENT
Revenues for the quarter ended June 30, 2004 were $2,826,825, an increase of 44.8% compared to revenues of $1,952,258 for the three months ended June 30, 2003. The Company reported comprehensive income for the quarter of $101,157 compared to comprehensive income of $49,044 for the second quarter of 2003. Comprehensive income for each period includes adjustments related to foreign currency translation and unrealized gains or losses on securities available for sale.
Excluding these adjustments, net income for the period was $83,110, or $0.00 per share compared with a net loss of $(72,395), or $0.00 per share for the comparable period in 2003. Total basic and diluted shares outstanding used in the calculation of EPS for both periods were 25,350,000.
Gross profit for the second quarter of 2004 was $854,527, compared with gross profit of $547,684 for the second quarter of 2003. Operating income for the quarter increased to $207,198 compared with an operating loss of ($16,616) for the year-ago period.
Gross profit margin for the three months ended June 30, 2004 was 30.2% compared with 28% for the same period in 2003. The increase is attributable to increased export sales that were characterized by higher margins compared to local sales. Higher overseas margins were partially offset by the ratio spread between the Euro and US Dollar and increased local competition resulting from shrinkage in the Israeli market. The Company does not anticipate any major changes to gross margin percentage during the remainder of 2004.
Revenues for the quarter included sales of approximately $.97 million to the local market, compared with local sales of $1.28 million for the second quarter of 2003. Net sales from exports increased approximately 177% to $1.86 million, from $.67 million in the second quarter of 2003. The increase in the export business is partially attributable to the sales of the Company's ballistic plates, blankets and lightweight vehicle armor kits that were recently introduced as new product offerings.
The Company expects the trend of increased export sales to continue in the third quarter, and it is anticipated that third quarter 2004 sales will exceed sales from the third quarter of 2003.
For the six months ended June 30, 2004, the Company reported revenues of $6,572,804, compared with revenues of $5,120,402 for the six months ended June 30, 2003. Comprehensive income for the first half of 2004 was $374,553 compared to comprehensive income of $245,336 for the six months ended June 30, 2003. Comprehensive income for each period includes adjustments related to foreign currency translation and unrealized gains or losses on securities available for sale.
Excluding these adjustments, net income for the period was $432,334 or $.02 per share, an increase of 325% compared with $101,717, or $0.00 per share for the comparable period in 2003.
Gross profit for the period was $1,820,766, compared with gross profit of $1,442,016 for the six months ended June 30, 2003. The Company reported operating income of $745,821 for the first six months of 2004, compared with $365,692 during the comparable period in 2003.
Sales to the local market for the first six months of 2004 were approximately $1.7 million, compared with local sales of $2.7 million for the same period in 2003. Export sales for the period increased approximately 103% to $4.9 million, from $2.4 million reported in the six-month period ended June 30, 2003.
Commenting on the results, Joseph Fostbinder, CEO of Defense Industries said, "We are extremely pleased with our second quarter results. We saw continued strength in the Company's export sales, which we believe is attributable to the successful implementation of our strategy to concentrate our efforts on international expansion. While our sales to the local market remain depressed, our 177% gain in second quarter export revenues offset the local decline and allowed us to achieve net revenue growth for the quarter."
He continued, "The growth trend in North America continued this quarter as we received an order for approximately $1 million for our vehicle armoring kits from a key customer in the region. This is a follow-on order to the approximately $1.7 million initial order made in the first quarter of this year, and we expect to see additional orders from this customer in the second half. We are pleased by the initial market acceptance of our vehicle armoring kit, which is a relatively new addition to the Defense Industries product family. We believe these initial results speak greatly to the quality of our products and enhance the stellar reputation we have earned with our customers worldwide.
"Additionally, we received orders, worth a total of $1,100,000 from customers in South & Central America. These follow-on orders for the Company's bulletproof vests were the result of our joint venture and increased sales and marketing efforts in the region. It has been a little over a year since our expansion into the South American market and we continue to experience significant and positive word-of-mouth exposure that has resulted in interest in a number of our products from potential new customers. Our South American sales and marketing efforts remain extremely aggressive, and we continue to believe this market represents a significant growth opportunity for the Company."
Mr. Fostbinder concluded, "We are extremely pleased with the results from our international markets and we remain confident in our ability to capitalize on the continued growth opportunities that exist for the Company. We remain committed to continuing the expansion of our export business, both securing new customers and enhancing relationships with our existing customers, as well as working to return our local business to historical levels as the Israeli economy picks up and spending resumes."
About Defense Industries International, Inc.
Defense Industries International, Inc. ("Defense Industries") (www.defense-industries.com) is a leading manufacturer and global provider of personal military and civilian protective equipment and supplies. Defense Industries' subsidiary, Export Erez Ltd., was formed and registered in 1983. Defense Industries' main products include body armor, bomb disposal suits and bullet-resistant vests and jackets; ballistic wall covers, helmets, plates and one-way protective windows; personal military equipment, battle pouch units and combat harness units; dry storage units, liquid logistics, tents and vehicle covers; and winter suits, sleeping bags and backpacks.
Defense Industries' products are used by military, law enforcement, border patrol enforcement and other special security forces, corporations, non-governmental organizations and individuals throughout the world. Customers include the Israel Defense Forces, the North Atlantic Treaty Organization (NATO), the United Nations Peacekeeping Forces and other U.N. organizations.
Defense Industries manufactures its own products, thereby enabling it to offer highly competitive pricing and to fulfill product orders on a rapid and efficient basis. Its manufacturing facilities meet American EQNET and international ISO 9001 standards. Quality control in the Company's manufacturing facilities is performed according to ISO 9001; MIL.STD.105D; MIL-I-45208A (for the U.S. Armed Forces); AQAP (for the German Armed Forces and NATO); and the National Institute of Justice (N.I.J.).
Defense Industries' strategic objective is to be the leading global provider of personal military and civilian protective equipment and supplies. Defense Industries intends to realize its strategic objective by, amongst other methods, selectively pursuing strategic acquisitions that enhance its product lines and geographic presence in an effort to consolidate its highly fragmented industry and to create a more diverse and global reach in its marketplace.
LENF - I just became too convinced that if UGHO, a stock with no fundamentals, could run 400% on pepper spray....that LENF should be able to do at least that much with electrical discharge weapons. So I bought @ $1.85 today.
thanks eom
LENF....if only those UGHO momos understood fundamentals....they'd be all over LENF. Oh well, here I am the bagholder again....until the next PR.
Anyone here look at LENF? Momo has slowed, but the stock has fundamentals:
Law Enforcement Associates Retains Former Vice President of Engineering at Tasertron
Monday September 20, 10:08 am ET
YOUNGSVILLE, N.C.--(BUSINESS WIRE)--Sept. 20, 2004--Law Enforcement Associates Corporation (OTCBB:LENF - News), a surveillance and security technology company, announced today that it has retained James McNulty, Sr. to an exclusive consulting agreement. Mr. McNulty was vice president for operations and engineering at Tasertron. While at Tasertron he invented the first less lethal anti-personnel land mines and sentinel systems that subdued combatants with electric shocks. Mr. McNulty is a member of the Institute of Electrical and Electronic Engineers and a Senior Member of the Society of Manufacturing Engineers. During his distinguished career, Mr.McNulty worked with Grumman Aircraft and Sperry Products designing radar systems and improvements to ultrasonic testing equipment. In addition, while at Lear Siegler, Mr. McNulty served as a program manager for several military R & D programs, including programs for design of the ignition inverters for the Polaris and Poseidon missile systems.
Commenting on the consulting agreement, Paul Feldman, President of LENF, stated, "We are very excited to be working with Mr. McNulty, an individual who brings over 30 years of experience in the electronics field. He will be instrumental in aiding Law Enforcement Associates in our efforts to market and manufacture Less Lethal, Electrical Discharge Weapons for which we have just acquired the patents." Mr. Feldman added, "In addition to his design duties, Jim McNulty will be responsible for designing and implementing our Law Enforcement training program for the use of our "Less Lethal" weapons."
About Law Enforcement Associates Corporation
Law Enforcement Associates, Inc. (LENF.OB) headquartered in Youngsville, N.C., manufactures and markets a diverse line of undercover surveillance products including a complete line of audio surveillance equipment. LEA currently markets to the Military, law enforcement, security and corrections personnel throughout the world, as well as governmental agencies, multinational corporations and non-governmental organizations. For more information on LEA, visit www.leacorp.com.
Forward-Looking Information:
The statements in this news release contain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve certain risks, assumptions and uncertainties, including the inability to generate and secure the necessary product sale, or the lack of acceptance of the company's products by its customers. In each case actual results may differ materially from such forward-looking statements. The company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results (expressed or modified) will not be realized.
--------------------------------------------------------------------------------
Contact:
Law Enforcement Associates
Paul Feldman, 919-554-4045
IR@Lea.com
tech, not me, here's the post I intended to reply to with that DD on John:
http://ragingbull.lycos.com/mboard/boards.cgi?board=BIPH&read=20498
But I still respectfully disagree with you. BIPH said the R&D has expanded with BSX to multiple divisions and multiple products. As the powerpoint slides show, the nanomagnetic coating is the base of BIPHs drug eluting technology....it's also the base for the interventional-MRI capabilites. I really don't think they came up with these ideas out of the blue....and on their own. I speculate it has everything to do with the R&D with BSX. Then you consider that they hired J. Lanzafame.....an ANPI employee......and ANPI's only active partner is BSX. Yes I think the R&D started with MRI-safety....but I think it has evolved to include BIPHs recent discussions about interventional-MRI....and drug-eluting capabilities....all enabled through BIPHs nanomagnetic coatings....which should command one big licensing fee.
From my speculative mindset, it seams almost too transparent to me. But all either of us can do is speculate.....I hope eventually we will see who is right....and we can have a good laugh at these silly speculations we were making when BIPH was a development stage penny stock!
IVAN was still a pretty impressive storm by the time it got up here to Philly. I'm just watching the tree in my backyard that hangs over my neighbors house....and hoping today isn't the day it falls on their house....my home owners insurance policy stinks...I don't want to have to deal with them!
It looks like that S-8 is to register the employee stock option shares that have been filed on Form 4s over the past few weeks? I think this brings the share count up to about 70M....and is still consistant with what the CEO has said about the equity partner seeking to purchase 10M shares.....that would generate the capital required for an AMEX listing while keeping the share count under 80M.
Looking at the Pre 14C filed yesterday I found this:
(2) Applicable percentage of ownership is based on 69,888,685 shares outstanding
as of August 31, 2004, together with applicable options for such shareholder.
Beneficial ownership is determined in accordance with the rules of the SEC and
includes voting and investment power with respect to shares. Shares subject to
options or warrants currently exercisable or exercisable within 60 days after
August 31, 2004 are included in the number of shares beneficially owned and are
deemed outstanding for purposes of computing the percentage ownership of the
person holding such options or warrants, but are not deemed outstanding for
computing the percentage of any other stockholder.
I have MDPA as a long-term hold from $0.74. I still see it as a good value anywhere under $1.50.
They reported 0.08 EPS last quarter. To be very conservative, I assume they can continue to post EPS of 0.04/quarter, still giving them a very conservative fwd P/E under 10.
Should get above $2 eventually IMO.
Prophet,
I just don't understand why you needed to create your own forum here.....and your own terminology with this "boosh" stuff?
Then there's your secret criteria that we're not worthy of knowing.....it really comes accross like you would prefer a situation of "the blind leading the blind".
I prefer an open dialogue about fundamentals and technicals using existing terminology.
It just seams like you might do better discussing your picks in an existing forum.
I can appreciate the fact you like The Dead, I'm also a Dead fan.
But I'm a humble student to the wise people I have encountered on these message boards over the years....the ones who can share their knowledge and information....and I don't follow self proclaimed gurus or prophets.
Good luck to you!
UGHO...darn!!!!! Now at $1.06. eom.
BIPH - Seams like the market likes the Pre14C filed yesterday? But volume is too low for it to be considered a strong indication.
Catfish, sounds like all you need is a little yard work, glad to hear you, your family, and your home escaped relatively unscathed. Just be glad you don't live on a flood plain!
Catfish, sorry for my alarmist post.
After reviewing this and thinking about it for a bit, I actually think this could be quite positive. This is preferred stock, not a preferred convertible....and definitely not a floorless convertible. Also, the filing says "These preferred shares will be identical to common shares accept for the liquidation preference." So they won't have any special voting rights.
So the way this looks to me is, they're trying to get this partner to pay a "premium over market", so they needed to throw them some kind of bone...so they went with preferred shares.
The CEO has said he's being very judicious in exercising the SBI financing, while trying to negotiate this investment from a partner. If they get this investment from a partner, I'm pretty sure they intend to cancel the SBI financing, which will limit dillution.
I actually think the CEO is being very respectful of the common shareholders here, as he is one himself. Actually, you'll see the BOD stock options issued this year are at $0.98/share, which also shows us common shareholders some more respect than I'm used to from a lot of these penny stock companies.
This is just some speculation by me, but the average of the SBI financing is $1.40/share, so maybe they're even trying to get a higher price than that?